We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.16 | -0.13% | 127.35 | 55,888 | 13:33:57 |
By Matt Grossman
Merck & Co. Inc. on Friday reported a larger profit in the second quarter despite declining revenue, as the company progressed on work towards treatments and vaccines for Covid-19.
The Kenilworth, N.J.-based pharmaceutical company said that the pandemic dragged on revenue in the latest quarter as it reduced people's non-Covid-19 health-care visits, putting pressure on prescriptions. Selling, general and administrative costs, as well as research and development expenses, were both lower in the quarter for Merck, due in part to declines in marketing, travel and meeting expenses.
Merck reported a second-quarter profit of $3 billion, or $1.18 a share, compared with a profit of $2.67 billion, or $1.03 a share, in the same three-month period a year earlier.
On an adjusted basis, Merck's profit was $1.37 a share. Analysts polled by FactSet had expected second-quarter adjusted earnings of $1.06 a share.
Merck's revenue in the quarter was $10.87 billion, down from $11.76 billion a year earlier. Analysts had forecast revenue of $10.4 billion.
Through partnerships with other companies and research institutions, Merck is developing two vaccines to prevent Covid-19--both of which are in pre-clinical development--as well as an oral antiviral medication for the disease, which is in Phase 2 clinical trials.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
July 31, 2020 07:35 ET (11:35 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions